Leukemia & lymphoma/Leukemia and lymphoma · 2007 · 133 citations · 14 references
MedicineNuclear MedicineOncologyChemotherapyHematologic OncologyOncologic Nuclear MedicineLymphoma ImagingMalignant NeoplasmsMinimal Residual DiseasePositron Emission TomographyRadiation TherapyTherapy Response AssessmentComparative Diagnostic AccuracyConsolidation EffectsDiagnostic Accuracy StudiesHodgkin Lymphoma RadiotherapyHodgkin Lymphoma TherapyHodgkin Lymphoma TreatmentMatched Groups DesignRelapsed Hodgkin Lymphoma
This study aimed at evaluating the role of consolidation radiation in a setting of Hodgkin's lymphoma (HL) patients, using event-free survival (EFS) as end point. Among 260 patients treated with induction chemotherapy for bulky HL, 160 patients achieved negative residual masses at 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) scans. They were randomly divided into two well-matched groups to receive either 32 Gy radiotherapy to bulky area or no further therapy. At a median follow-up of 40 months, histology showed a malignancy in 14% of patients in the chemotherapy-only group (HL, 11 patients) and in 4% of patients in the chemotherapy + radiotherapy group (HL, 2 patients; carcinoma in previously irradiated area, 1 patient) (P = 0.03). All the relapses in the chemotherapy-only group involved the bulky site and the contiguous nodal regions. Thus, the overall diagnostic accuracy of FDG-PET to exclude future relapses in the patients nonprotected by radiotherapy was 86% with a false-negative rate of 14%. Our study suggests that the addition of irradiation helps improve EFS in HL patients with post-chemotherapy FDG-PET-negative residual masses.
14
Malik E. Juweid, Sigrid Stroobants, Otto S. Hoekstra et al. · Journal of Clinical Oncology · 2007 · 1.3K citations · Full text
Medicine, Nuclear Medicine, Oncology +16
Guy Jérusalem, Yves Béguin, Marie‐France Fassotte et al. · Blood · 1999 · 556 citations
Medicine, Nuclear Medicine, Oncology +16